Skip to main content
Midas Edge

Jaguar Health Inc

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

JAGX$0.44+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Comprehensive Losses

​​​​​​​​​​​​
​ · Three Months Ended · ​ · Six Months Ended
​ · June 30, · ​ · June 30,
(In thousands, except share and per share data) · 2024 · 2023 · 2024 · 2023
Net loss$(9,628)​$(12,291)​$(18,996)​$(24,688)
Other comprehensive income (loss)​(94)​​183​​124​​(49)
Net comprehensive loss$(9,722)​$(12,108)​$(18,872)​$(24,737)
Common stockholders:​​​​​​​​​​​
Net loss attributable to common stockholders$(9,492)​$(12,150)​$(18,718)​$(24,352)
Other comprehensive income (loss) attributable to common stockholders​​​​​​​​​​​
Translation adjustments​(82)​​161​​110​​(43)
Net comprehensive loss attributable to common stockholders$(9,574)​$(11,989)​$(18,608)​$(24,395)
Non-controlling interests:​​​​​​​​​​​
Net loss attributable to non-controlling interests$(136)​$(141)​$(278)​$(336)
Other comprehensive income (loss) attributable to non-controlling interests​​​​​​​​​​​
Translation adjustments​(12)​​22​​14​​(6)
Net comprehensive loss attributable to non-controlling interests$(148)​$(119)​$(264)​$(342)
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · Redeemable preferred stock · ​ · Series G Convertible preferred stock · ​ · Series I Convertible preferred stock · ​ · Common Stock - voting · ​ · Common Stock - non-voting · ​ · Additional · ​ · Noncontrolling · ​ · Accumulated · ​ · Accumulatedother comprehensive · ​ · TotalStockholders'
(In thousands, except share data) · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · paid-in capital · interest · deficit · loss · Equity
Balances as of March 31, 2024​99​$2,485​—​$—​—​$—​4,557,991​$—​9​$—​$329,674​$(180)​$(317,215)​$(460)​$11,819
Common stock issued in At the Market offering, net of issuance and offering costs of $67​—​​—​—​​—​—​​—​2,829,987​​—​—​​—​​12,668​​—​​—​​—​​12,668
Common shares issued to Iliad in exchange of notes payable and accrued interest​—​​—​—​​—​—​​—​393,700​​—​—​​—​​1,421​​—​​—​​—​​1,421
Common stock issued to Irving in exchange of notes payable and accrued interest​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​—​​—​​—​​—
Common stock issued upon exercise of restricted stock units​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​—​​—​​—​​—
Common stock issued to third party for services​—​​—​—​​—​—​​—​45,719​​—​—​​—​​9​​—​​—​​—​​9
RSUs issued​—​​—​—​​—​—​​—​212​​—​—​​—​​—​​—​​—​​—​​—
Warrants issued in PIPE financing​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​—​​—​​—​​—
Warrants issued to Irving in exchange of Standstill​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​—​​—​​—​​—
Warrants issued to Iliad in exchange of Standstill​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​—​​—​​—​​—
Stock-based compensation​—​​—​—​​—​—​​—​—​​—​—​​—​​383​​—​​—​​—​​383
Net loss​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​(136)​​(9,492)​​—​​(9,628)
Translation loss​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​(12)​​—​​(82)​​(94)
Balances as of June 30, 2024​99​$2,485​—​$—​—​$—​7,827,609​$—​9​$—​$344,155​$(328)​$(326,707)​$(542)​$16,578
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · Redeemable preferred stock · ​ · Series G Convertible preferred stock · ​ · Series I Convertible preferred stock · ​ · Common Stock - voting · ​ · Common Stock - non-voting · ​ · Additional · ​ · Noncontrolling · ​ · Accumulated · ​ · Accumulatedother comprehensive · ​ · TotalStockholders'
(In thousands, except share data) · Shares · Amount · Shares · Amount · Shares · Amount · ​ · Shares · Amount · Shares · Amount · paid-in capital · interest · deficit · loss · Equity
Balances as of March 31, 2023​—​$—​—​$—​—​$—​236,262​$—​9​$—​$287,384​$310​$(279,150)​$(884)​$7,660
Preferred stock issued in PIPE financing, net of issuance and offering costs of $12​—​​—​137​​—​—​​—​—​​—​—​​—​​612​​—​​—​​—​​612
Preferred stock issued to Streeterville in exchange for notes payable and accrued interest​—​​—​—​​—​—​​—​—​​—​—​​—​​1,730​​—​​—​​—​​1,730
Preferred stock issued to Irving in exchange for notes payable and accrued interest​—​​—​—​​—​—​​—​—​​—​—​​—​​758​​—​​—​​—​​758
Common stock issued in At the Market offering, net of issuance and offering costs of $147​—​​—​—​​—​—​​—​50,325​​—​—​​—​​1,553​​—​​—​​—​​1,553
Common stock issued to Irving in exchange for notes payable and accrued interest​—​​—​—​​—​—​​—​31,811​​—​—​​—​​1,393​​—​​—​​—​​1,393
Common stock issued upon exercise of restricted stock units​—​​—​—​​—​—​​—​219​​—​—​​—​​9​​—​​—​​—​​9
Common stock issued to third party for services​—​​—​—​​—​—​​—​3​​—​—​​—​​—​​—​​—​​—​​—
Warrants issued in PIPE financing​—​​—​—​​—​—​​—​—​​—​—​​—​​1,235​​—​​—​​—​​1,235
Warrants issued to Irving in exchange for Standstill​—​​—​—​​—​—​​—​—​​—​—​​—​​1,935​​—​​—​​—​​1,935
Warrants issued to Iliad in exchange for Standstill​—​​—​—​​—​—​​—​—​​—​—​​—​​535​​—​​—​​—​​535
Stock-based compensation​—​​—​—​​—​—​​—​—​​—​—​​—​​518​​—​​—​​—​​518
Net loss​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​(141)​​(12,150)​​—​​(12,291)
Translation gain​—​​—​—​​—​—​​—​—​​—​—​​—​​—​​22​​—​​161​​183
Balances as of June 30, 2023​—​$—​137​$—​—​$—​318,620​$—​9​$—​$297,662​$191​$(291,300)​$(723)​$5,830
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.